Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060.

Slides:

Advertisements

Similar presentations

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

Advertisements

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.

Philip J. Barter, et al. Circulation 2011;124:

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

OUTCOME MEASURES IN PsA: IMMUNOHISTOLOGY Oliver FitzGerald.

Atherosclerotic lesion area within the aortic sinus of apoE - / - and apoE - / - - hCRP + mice Gideon M. Hirschfield et al. PNAS 2005;102:8309– 8314.

Westerweel PE et al. Eur Heart J 2008;29:

Baseline Characteristics of the Patients Part I

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

Section 7: Aggressive vs moderate approach to lipid lowering

Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Miral R. Sadaria, MD, Amy E. Reppert, MD, Jessica A

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Rachel Truitt et al. BTS 2018;3:

Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Loss of DGKζ and Cbl-b results in a greater percentage of splenic CD8+ T cells with an activated phenotype. Loss of DGKζ and Cbl-b results in a greater.

FLC treatment results in an increase in ploidy in a significant fraction of cells. FLC treatment results in an increase in ploidy in a significant fraction.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Histological and mRNA analysis of the inflammatory cytokines in the vehicle‐ or etifoxine‐treated mice at onset of clinical symptoms.A–D.At day 10 p.i.,

Baseline Characteristics by hs-CRP

Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.

David J.A. Jenkins et al. JACC 2018;71:

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

CD4 expressing CD161 and CD8 expressing CD161int are preserved in CVID

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Baseline characteristics of study population

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

CD151-knockdown cells show an aberrant spreading response to PMA

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Baseline Clinical and Angiographic Characteristics of All Patients With Aspirated Intracoronary Material (n211) S.Z.H. Rittersma, Circulation. 2005;111:

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Immunologic and pharmacokinetic studies.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

BH3 profiling reveals BCL-2 dependence in ETP-ALL in a separate cohort of DFCI patient samples. BH3 profiling reveals BCL-2 dependence in ETP-ALL in a.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Induction of apoptosis by statins in NB4 cells and NB4 variant cell lines. Induction of apoptosis by statins in NB4 cells and NB4 variant cell lines. A,

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Expression of CD40L and CD40 in human vascular atherosclerotic lesions in situ. Expression of CD40L and CD40 in human vascular atherosclerotic lesions.

Hcy decreases VEGFR1/2 and Angs (Ang1, Ang2) gene transcription

Mice with a B cell–specific deletion of Ets1 do not have increased CD4+ T cell activation. Mice with a B cell–specific deletion of Ets1 do not have increased.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Serum Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Plaque Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Percentage of plaques with minor or heavy staining for CD68 positive cells Bart A.N. Verhoeven, et al. Stroke 2006;37:

Patients treated with high statin dose showed a significant decrease in MMP-8 activity, whereas a tendency is observed for MMP-9 Bart A.N. Verhoeven, et al. Stroke 2006;37:

MMP-8 and -9 levels of atherosclerotic plaques with moderate/heavy (+) staining for CD68 positive cells compared with plaques with no/minor (-) staining and different groups of statin treatment Bart A.N. Verhoeven, et al. Stroke 2006;37:

MMP-8 and -9 levels in a selected group of patients Selection was based on CD68 plaque staining and atorvastatin treatment Bart A.N. Verhoeven, et al. Stroke 2006;37: